News stories about Neurocrine Biosciences (NASDAQ:NBIX) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Neurocrine Biosciences earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.2022226447798 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:
- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Active Stock Evaluation – Nasdaq Journal (press release) (nasdaqjournal.com)
- Neurocrine, Ingrezza Sail Into 2018 – Seeking Alpha (seekingalpha.com)
- FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX) (americanbankingnews.com)
- 10 Top Penny Stocks to Watch This Week for Under $2 (moneymorning.com)
- CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY – Nasdaq (nasdaq.com)
Several brokerages have recently issued reports on NBIX. Jefferies Group raised their price objective on shares of Neurocrine Biosciences to $105.00 and gave the stock a “buy” rating in a research note on Friday, January 5th. Oppenheimer lifted their price target on shares of Neurocrine Biosciences from $70.00 to $85.00 and gave the stock an “outperform” rating in a research note on Thursday, November 2nd. Citigroup reissued a “buy” rating and set a $79.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Needham & Company LLC reissued a “buy” rating and set a $86.00 price objective on shares of Neurocrine Biosciences in a report on Thursday, November 2nd. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and issued a $76.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, October 25th. One analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $81.13.
Neurocrine Biosciences (NASDAQ:NBIX) opened at $81.37 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 14.37 and a current ratio of 14.38. Neurocrine Biosciences has a 12-month low of $38.43 and a 12-month high of $83.84.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The firm had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the previous year, the firm posted ($0.43) EPS. research analysts predict that Neurocrine Biosciences will post -1.61 EPS for the current fiscal year.
In other news, insider Darin Lippoldt sold 1,979 shares of the company’s stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total transaction of $157,053.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kyle Gano sold 24,818 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the sale, the insider now owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,405 shares of company stock worth $8,588,519. Company insiders own 4.80% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Neurocrine Biosciences (NASDAQ:NBIX) Share Price” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this piece can be viewed at https://www.thelincolnianonline.com/2018/01/14/neurocrine-biosciences-nbix-getting-somewhat-favorable-media-coverage-report-finds-updated-updated-updated.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.